Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on CKD-397 Bioavailability in Healthy Males
NCT02615782Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Dec 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tadalafil + tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Curve to the last measurable concentration at 72 hours and Maximum Plasma Concentration at 72 hours. Started Dec 2015; status: completed.
02
Drugs
tadalafil + tamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02615782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02615782.